Association between physical activity and risk of bleeding in children with hemophilia

JAMA

Volumn 308, Issue 14, 2012, Pages 1452-1459

  Broderick, Carolyn R ^a,b,c,d   Herbert, Robert D ^d,e   Latimer, Jane ^a,d   Barnes, Chris ^f   Curtin, Julie A ^c   Mathieu, Erin ^a   Monagle, Paul ^f,g   Brown, Simon A ^h  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^d GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^e NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^f ROYAL CHILDREN'S HOSPITAL   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR;

ARTICLE; AUSTRALIA; BASKETBALL; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DISEASE SEVERITY; HEMOPHILIA A; HEMOPHILIA B; HUMAN; MAJOR CLINICAL STUDY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SWIMMING;

EID: 84867166712     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.12727     Document Type: Article

References (26)

1. Aledort LM, Haschmeyer RH, Pettersson H; The Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. J Intern Med. 1994;236(4):391-399.
2. Weigel N, Carlson BR. Physical activity and the hemophiliac: yes or no? Am Correct Ther J. 1975;29(6):197-205.
3. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis vs episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535-544.
4. Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM; ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost. 2011;9(4):700-710.
5. Srivastava A. Factor replacement therapy in haemophilia - are there models for developing countries? Haemophilia. 2003;9(4):391-396.
6. Maclure M, Mittleman MA. Should we use a case-crossover design? Annu Rev Public Health. 2000;21:193-221.
7. Broderick CR, Herbert RD, Latimer J, Barnes C, Curtin JA, Monagle P. Estimation of transient increases in bleeding risk associated with physical activity in children with haemophilia. BMC Blood Disord. 2008;8:2.
8. Fischer K, Astermark J, van der Bom JG, et al. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia. 2002;8(6):753-760.
9. Anderson A, Forsyth A. Playing it Safe; Bleeding Disorders, Sports and Exercise. In: Foundation NH, ed. New York, NY: National Hemophilia Foundation; 2005.
10. Björkman S, Shapiro AD, Berntorp E. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemophilia. 2001;7(2):133-139.
11. Barnes C, Lillicrap D, Pazmino-Canizares J, et al. Pharmacokinetics of recombinant factor VIII (Kogenate-FS) in children and causes of inter-patient pharmacokinetic variability. Haemophilia. 2006;12(suppl 4):40-49.
12. Blanchette VS, Shapiro AD, Liesner RJ, et al; rAHFPFM Clinical Study Group. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost. 2008;6(8):1319-1326.
13. Poon M-C, Lillicrap D, Hensman C, Card R, Scully M-F. Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study. Thromb Haemost. 2002;87(3):431-435.
14. Carlsson M, Berntorp E, Björkman S, Lindvall K. Pharmacokinetic dosing in prophylactic treatment of hemophilia A. Eur J Haematol. 1993;51(4):247-252.
15. Bjorkman S, Carlsson M. The pharmacokinetics of factor VIII and factor IX: Methodology, pitfalls and applications. Haemophilia. 1997;3(1):1-8.
16. Karafoulidou A, Suarez E, Anastasopoulou I, et al. Population pharmacokinetics of recombinant factor VIII:C (ReFacto) in adult HIV-negative and HIV-positive haemophilia patients. Eur J Clin Pharmacol. 2009;65(11):1121-1130.
17. Rothman KJ, Greenland S, Lash TL. Modern epidemiology. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2008.
18. Rodrigues L, Kirkwood BR. Case-control designs in the study of common diseases: updates on the demise of the rare disease assumption and the choice of sampling scheme for controls. Int J Epidemiol. 1990;19(1):205-213.
19. Dupont WD. Power calculations for matched casecontrol studies. Biometrics. 1988;44(4):1157-1168.
20. Twisk J. Applied Longitudinal Data Analysis for Epidemiology: A Practical Guide. Cambridge, England: Cambridge University Press; 2003.
21. Australian Bleeding Disorders Registry. https://www.abdr.blood.gov.au ed2011.
22. Ross C, Goldenberg NA, Hund D, Manco-Johnson MJ. Athletic participation in severe hemophilia: bleeding and joint outcomes in children on prophylaxis. Pediatrics. 2009;124(5):1267-1272.
23. Tiktinsky R, Kenet G, Dvir Z, et al. Physical activity participation and bleeding characteristics in young patients with severe haemophilia. Haemophilia. 2009;15(3):695-700.
24. Collins PW, Blanchette VS, Fischer K, et al; rAHFPFM Study Group. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost. 2009;7(3):413-420.
25. van den Berg HM, De Groot PHG, Fischer K. Phenotypic heterogeneity in severe hemophilia. J Thromb Haemost. 2007;5(suppl 1):151-156.
26. Broderick CR, Herbert RD, Latimer J, van Doorn N. Patterns of physical activity in children with haemophilia [published online July 5, 2012]. Haemophilia. doi:10.1111/j.1365-2516.2012.02904.x.